- Home
- NAVN vs NAMS Comparison
NAVN vs NAMS Comparison
Compare NAVN & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAVN | NAMS |
|---|---|---|
| Founded | 2015 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.1B |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | NAVN | NAMS |
|---|---|---|
| Price | $14.98 | $35.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | $25.50 | ★ $46.40 |
| AVG Volume (30 Days) | ★ 1.5M | 1.1M |
| Earning Date | 12-15-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $656,339,000.00 | $35,243,000.00 |
| Revenue This Year | $27.24 | N/A |
| Revenue Next Year | $23.83 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 63.16 | 4.91 |
| 52 Week Low | $11.76 | $14.06 |
| 52 Week High | $22.75 | $42.00 |
Technical Indicators
Market Signals| Indicator | NAVN | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 45.27 |
| Support Level | N/A | $32.85 |
| Resistance Level | N/A | $37.41 |
| Average True Range (ATR) | 0.00 | 1.77 |
| MACD | 0.00 | -0.36 |
| Stochastic Oscillator | 0.00 | 28.63 |
Price Performance
Historical ComparisonAbout NAVN Navan Inc.
Navan Inc is an end-to-end, AI-powered software platform built to simplify the world-wide business T&E experience, benefiting users, customers, and suppliers. Its leveraged technology to reimagine business travel. The company deliver delightful, personalized experiences for users, efficiency and control for customers, and direct market access for suppliers-all powered by its proprietary AI framework, Navan Cognition. Geographically, the company operates in United States, United Kingdom and Other countries, of which United States derives maximum revenue.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.